# US Opioid Withdrawal Treatment Market > US Opioid Withdrawal Treatment Market Research Report By Treatment Type (Medications, Therapeutic Procedures, Psychological Counseling, Support Groups), By Route of Administration (Oral, Injectable, Transdermal, Nasal), By Patient Type (Inpatient, Outpatient, Emergency) and By Age Group (Children, Adolescents, Adults, Elderly) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.15% - **2024:** $ 675.69 Million - **2025:** $ 710.49 Million - **2035:** $ 1,173.96 Million - **Key Players:** Indivior PLC (GB), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (IL), Alkermes PLC (IE), Purdue Pharma L.P. (US), Horizon Therapeutics PLC (IE), NantKwest Inc. (US), Camurus AB (SE) **Report ID:** MRFR/HC/16106-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-opioid-withdrawal-treatment-market-17634 --- ## Market Summary ## **US Opioid Withdrawal Treatment Market Overview** As per MRFR analysis, the US Opioid Withdrawal Treatment Market Size was estimated at 696.15 (USD Million) in 2023. The US Opioid Withdrawal Treatment Market Industry is expected to grow from 750 (USD Million) in 2024 to 1,300 (USD Million) by 2035. The US Opioid Withdrawal Treatment Market CAGR (growth rate) is expected to be around 5.128% during the forecast period (2025 - 2035). ### **Key US Opioid Withdrawal Treatment Market Trends Highlighted** The US Opioid Withdrawal Treatment Market is witnessing significant trends driven by various factors. A major driver of this market is the alarming increase in opioid addiction and overdose deaths across the United States, leading to heightened demand for effective withdrawal treatment solutions. The Centers for Disease Control and Prevention (CDC) reports that opioid overdose deaths have reached epidemic proportions, pushing healthcare providers and policymakers to seek comprehensive treatment options. This has resulted in the growth of treatments that combine medication-assisted therapy with behavioral health support, offering a more holistic approach to recovery. Opportunities within the market can be captured through advancements in telemedicine and digital health platforms. These technologies allow patients to access treatment and support remotely, making it easier for those in rural or underserved areas to engage with care services. Moreover, innovative drug development focusing on non-addictive alternatives is gaining momentum, presenting a chance for new entrants to disrupt traditional treatment pathways and improve patient outcomes. Recently, there has been a notable trend towards integrating mental health services with substance use disorder treatments, emphasizing the importance of addressing co-occurring disorders in recovery programs. Support from federal initiatives aimed at combating the opioid crisis, such as funding for treatment and prevention programs, further reinforces this trend. Additionally, there is a growing emphasis on community-based approaches, fostering collaborative efforts between healthcare providers and local organizations to create supportive environments for individuals undergoing withdrawal treatment. As the US continues to address the complexities of the opioid crisis, these evolving trends reflect a commitment to increasing access to effective withdrawal treatment options for those in need. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Opioid Withdrawal Treatment Market Drivers** ### **Increasing Opioid Addiction Rates** The US Opioid Withdrawal Treatment Market Industry is significantly driven by the rising rates of opioid addiction, which have been declared a national public health crisis by the U.S. Department of Health and Human Services. According to the National Institute on Drug Abuse, approximately 2 million Americans had a prescription opioid use disorder in 2018, and about 1.6 million had a heroin use disorder. The ongoing impact of opioid addiction leads to an increased demand for effective withdrawal and treatment solutions. Furthermore, more healthcare providers and facilities are focusing on integrating opioid withdrawal therapies into their protocols, which emphasizes a robust growth trajectory for the industry. Government initiatives, such as the Substance Abuse and Mental Health Services Administration's programs, aim to expand treatment access and methodologies, fostering innovation and development in the US Opioid Withdrawal Treatment Market. ### **Advancements in Treatment Options** The US Opioid Withdrawal Treatment Market Industry is also significantly influenced by advancements in treatment options, including medications and therapeutic techniques. Recent developments, such as the introduction of buprenorphine and methadone as standard care for opioid withdrawal, have improved patient outcomes. According to the American Society of Addiction Medicine, these medications decrease withdrawal symptoms, with studies indicating that individuals receiving medication-assisted treatment are more likely to remain in treatment and achieve recovery compared to those receiving only counseling. The growing research and development efforts by organizations like the National Institutes of Health are expected to result in new therapies, thereby expanding the market. ### **Increased Government and Institutional Support** The US Opioid Withdrawal Treatment Market Industry benefits from heightened government and institutional support aimed at combating the opioid crisis. Legislative actions and funding initiatives, such as the 21st Century Cures Act, have allocated resources to support treatment programs and healthcare services. The Centers for Disease Control and Prevention has reported a significant uptick in public funding for treatment programs, with estimated funding levels needing to rise towards $10 billion annually to effectively address the opioid epidemic. This support not only provides funding for treatment initiatives but also helps in public education and integration of comprehensive treatment strategies, enhancing the overall market landscape. ## **US Opioid Withdrawal Treatment Market Segment Insights** ### **Opioid Withdrawal Treatment Market Treatment Type Insights** The US Opioid Withdrawal Treatment Market showcases a diverse range of treatment options categorized under the Treatment Type segment, reflecting a multi-faceted approach to addressing opioid dependency. Medications, encompassing a variety of pharmacological solutions, play a crucial role in alleviating withdrawal symptoms and facilitating recovery, thus significantly contributing to the overall effectiveness of treatment plans. Therapeutic Procedures, which include actions tailored to physically assist in the process of withdrawal, provide an essential layer of support, ensuring that patients receive attentive care during this critical phase of their recovery journey. Psychological Counseling is equally important, as it addresses the mental health issues associated with opioid addiction, offering coping strategies and reinforcing motivation towards sustainable recovery. Support Groups deliver community-based aid, fostering a sense of belonging and connectedness among individuals facing similar challenges, which can enhance the likelihood of successful outcomes. The prevalence of the opioid crisis in the US underscores the importance of these Treatment Type approaches. The coordinated efforts to manage withdrawal symptoms and provide holistic care underscore the multi-dimensional nature of effective treatment. These strategies help to mitigate risks associated with relapse and improve the overall quality of life for individuals affected. As the awareness surrounding opioid addiction continues to grow, the demand for diverse treatment methods is expected to follow suit. US Opioid Withdrawal Treatment Market revenue will benefit from this evolving landscape, emphasizing the need for a robust framework that integrates these various treatment types to support patients through their recovery process. Market trends indicate a growing recognition of the importance of addressing both the physical and psychological aspects of addiction, which will enhance the effectiveness of treatment offerings. As challenges persist in combatting the opioid epidemic, these treatment options stand as vital components in the broader strategy toward overcoming addiction, signifying meaningful opportunities for growth and advancement within the US Opioid Withdrawal Treatment Market segmentation. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Opioid Withdrawal Treatment Market Route of Administration Insights** The Route of Administration segment within the US Opioid Withdrawal Treatment Market is crucial in determining the effectiveness and accessibility of treatment options available for individuals facing opioid dependence. This segment encompasses various methods such as Oral, Injectable, Transdermal, and Nasal administration, each offering unique benefits and challenges. Oral administration is widely preferred due to its convenience and patient compliance, while Injectable treatments can provide rapid relief, addressing acute withdrawal symptoms effectively. Transdermal systems allow for sustained drug release, offering a continuous therapeutic effect, which is particularly useful for long-term management. Nasal delivery systems have gained traction as they can bypass the gastrointestinal tract, providing quicker onset of action. As the prevalence of opioid use disorder continues to rise in the US, with the Centers for Disease Control and Prevention reporting significant mortality rates, the adoption of diverse administration routes becomes paramount. Enhanced understanding of patient preferences and the pharmacokinetic profiles of these routes will shape future treatment strategies and contribute to better healthcare outcomes in addressing opioid withdrawal. The focus on product development tailored to these routes reflects a robust market growth opportunity, underscoring the importance of this segment in the broader context of the US Opioid Withdrawal Treatment Market. ### **Opioid Withdrawal Treatment Market Patient Type Insights** The Patient Type segment of the US Opioid Withdrawal Treatment Market plays a critical role in addressing the growing opioid crisis, which has become a significant public health challenge in the United States. Each category—Inpatient, Outpatient, and Emergency—offers tailored approaches to treatment, catering to diverse patient needs. Inpatient care is often necessary for individuals requiring intensive support, as it allows for constant monitoring and comprehensive medical intervention. Outpatient treatment provides flexibility, enabling patients to receive help while maintaining daily responsibilities, which is crucial for long-term recovery. Emergency interventions are vital for acute cases, where immediate care can prevent complications and initiate the withdrawal process safely. The combination of these treatment methods aligns with the increasing recognition that effective opioid withdrawal solutions must accommodate varying patient circumstances and preferences. This segmentation not only enhances the overall efficiency of the US Opioid Withdrawal Treatment Market but also addresses the pressing need for accessible and effective care options in response to the epidemic, ultimately fostering better patient outcomes and supporting recovery efforts nationwide. As demand continues to rise, the market remains focused on optimizing treatment pathways to ensure that all patients receive the appropriate level of care. ### **Opioid Withdrawal Treatment Market Age Group Insights** The US Opioid Withdrawal Treatment Market, segmented by Age Group, encompasses Children, Adolescents, Adults, and the Elderly, each presenting unique challenges and opportunities in opioid withdrawal management. The increasing prevalence of opioid dependency in Adults is a significant driver, as this group often requires tailored treatment strategies due to associated mental health issues and co-occurring disorders. Adolescents are emerging as a critical demographic due to the rising rates of opioid misuse within this age group, highlighting the need for age-appropriate treatment programs that take into account their developmental and psychological needs. Furthermore, Children, although less frequently affected, represent a vulnerable population requiring special attention and careful handling due to the complexities involved in treatment and the potential long-term impacts on their health. The Elderly demographic is also noteworthy, as they often face unique health complications that complicate withdrawal treatment, making it imperative for healthcare providers to adopt comprehensive approaches tailored to their specific needs. Understanding these segments enriches the insight into the dynamics of the US Opioid Withdrawal Treatment Market and underscores the necessity for targeted interventions that can enhance treatment efficacy across different age groups. Overall, the market growth in the US reflects the increasing urgency to address opioid dependency, driven by demographic insights and evolving treatment approaches. ## **US Opioid Withdrawal Treatment Market Key Players and Competitive Insights** The US Opioid Withdrawal Treatment Market has been under significant scrutiny in recent years due to the alarming rise in opioid addiction and the associated withdrawal symptoms faced by many individuals. This market is characterized by various treatment modalities aimed at alleviating withdrawal symptoms and facilitating the recovery of patients struggling with opioid dependency. The competitive landscape of this market involves a range of stakeholders, including pharmaceutical companies, treatment centers, and healthcare providers, all of whom are striving to innovate and improve treatment outcomes for their patients. The increasing prevalence of opioid use disorders has spurred investments and research into more effective withdrawal management strategies, ultimately reshaping the dynamics between competitors. With the growing recognition of opioid dependency as a public health crisis, companies are not only competing for market share but also for patient trust and regulatory approvals for their treatment solutions. Psychemedics has established a notable presence in the US Opioid Withdrawal Treatment Market primarily through its innovative hair drug testing technology. This proprietary method enables the identification of drug use over an extended period, providing valuable insights that enhance patient treatment strategies. The strength of Psychemedics lies in its unique ability to deliver reliable and comprehensive drug testing results, which not only aids medical professionals in making informed treatment decisions but also supports compliance monitoring for patients undergoing withdrawal therapy. The company has positioned itself as a leader in the drug testing segment, leveraging its technological advancements and solid reputation to carve out a significant niche within the opioid withdrawal treatment landscape. RiverMend Health has been a key player in the US Opioid Withdrawal Treatment Market, offering a comprehensive suite of services designed to address the needs of individuals struggling with opioid addiction. The company provides a continuum of care that includes inpatient, outpatient, and residential treatment options tailored to manage withdrawal symptoms effectively. RiverMend Health is known for its patient-centered approach, which combines evidence-based therapies with personalized treatment plans to enhance recovery outcomes. The company has also engaged in strategic mergers and acquisitions to expand its service offerings and market reach, effectively positioning itself as a notable entity in the sector. With a focus on accessibility and comprehensive care, RiverMend Health continues to strengthen its influence within the US opioid withdrawal treatment market. ### **Key Companies in the US Opioid Withdrawal Treatment Market Include** ## **US Opioid Withdrawal Treatment Market Industry Developments** The US Opioid Withdrawal Treatment Market has been witnessing significant developments recently, particularly as the demand for effective treatment options continues to grow amid the opioid crisis. As of October 2023, companies like Indivior and Alkermes are advancing therapeutic solutions, with Indivior focusing on innovative formulations for opioid addiction treatment. RiverMend Health has also expanded its services to provide comprehensive care for individuals dealing with substance use disorders. Notably, in March 2023, Purdue Pharma announced a settlement on its bankruptcy plan, aiming to direct funds toward addiction treatment initiatives, which reflects a shift in corporate responsibility amid ongoing litigation related to the opioid epidemic. Moreover, Zynerba Pharmaceuticals is making strides in cannabinoid-based therapies, enhancing the scope of treatment methods available. In terms of mergers and acquisitions, in April 2023, Appian Health announced a strategic acquisition to bolster its treatment infrastructure. The market valuation continues to rise as legislative changes support increased funding for addiction treatment services, driving growth for key players like Braeburn Pharmaceuticals and Thermo Fisher Scientific. Over the past two years, the focus on integrated treatment approaches has gained momentum, allowing companies to play a more pivotal role in combating opioid dependence in the US. ## **US Opioid Withdrawal Treatment Market Segmentation Insights** ### **Opioid Withdrawal Treatment Market Treatment Type Outlook** ### **Opioid Withdrawal Treatment Market Route of Administration Outlook** ### **Opioid Withdrawal Treatment Market Patient Type Outlook** ### **Opioid Withdrawal Treatment Market Age Group Outlook** ## Market Drivers ### Increased Focus on Mental Health The growing recognition of the link between mental health and substance use disorders is influencing the opioid withdrawal-treatment market. Mental health issues often co-occur with opioid addiction, necessitating integrated treatment approaches. As healthcare providers increasingly adopt holistic models that address both mental health and addiction, the demand for comprehensive withdrawal treatments is likely to rise. This shift in focus is supported by research indicating that individuals with co-occurring disorders benefit from integrated care. Consequently, the opioid withdrawal-treatment market is poised for growth as more providers implement strategies that encompass both mental health and addiction treatment. ### Government Initiatives and Funding Government initiatives aimed at combating the opioid crisis are playing a crucial role in shaping the opioid withdrawal-treatment market. Federal and state governments have allocated substantial funding to support treatment programs and research into effective therapies. For instance, the 21st Century Cures Act has provided billions in funding for mental health and substance use disorder treatment. This financial support is essential for developing new treatment modalities and expanding access to existing therapies. As these initiatives continue to evolve, they are expected to bolster the opioid withdrawal-treatment market, ensuring that more individuals receive the necessary care and support. ### Advancements in Treatment Modalities Innovations in treatment modalities are transforming the opioid withdrawal-treatment market. New pharmacological approaches, such as the development of non-opioid medications and combination therapies, are emerging as effective alternatives for managing withdrawal symptoms. Research indicates that medications like buprenorphine and naltrexone are gaining traction, providing patients with safer options. Additionally, behavioral therapies are being integrated into treatment plans, enhancing overall effectiveness. As these advancements continue to unfold, they are expected to attract more individuals seeking treatment, thereby contributing to the growth of the opioid withdrawal-treatment market. ### Increasing Awareness of Opioid Addiction The opioid withdrawal-treatment market is experiencing growth due to heightened awareness surrounding opioid addiction. Public health campaigns and educational initiatives have significantly increased understanding of the risks associated with opioid use. This awareness has led to a greater demand for treatment options, as individuals seek help for withdrawal symptoms. According to the Substance Abuse and Mental Health Services Administration, approximately 2 million individuals in the US suffer from opioid use disorder, highlighting the urgent need for effective treatment solutions. As awareness continues to rise, the opioid withdrawal-treatment market is likely to expand, with more individuals seeking assistance and healthcare providers responding to this demand. ### Rising Incidence of Opioid Overdose Deaths The alarming rise in opioid overdose deaths is a significant driver of the opioid withdrawal-treatment market. Data from the Centers for Disease Control and Prevention indicates that opioid overdoses have surged, with over 70,000 deaths reported in a single year. This crisis has prompted urgent calls for effective withdrawal treatments, as families and communities seek solutions to mitigate the devastating impact of addiction. The increasing mortality rates associated with opioid use disorder are likely to drive demand for comprehensive treatment options, thereby expanding the opioid withdrawal-treatment market as stakeholders respond to this pressing public health issue. ## Future Outlook The [Opioid Withdrawal Treatment Market](https://www.marketresearchfuture.com/reports/opioid-withdrawal-treatment-market-8123) is projected to grow at 5.15% CAGR from 2025 to 2035, driven by increasing demand for effective treatment options and innovative therapies. **New opportunities:** - Development of telehealth platforms for remote patient monitoring - Integration of AI-driven analytics for personalized treatment plans - Expansion of partnerships with pharmacies for medication-assisted treatment access By 2035, the market is expected to achieve substantial growth and enhanced treatment accessibility. ## Segment Insights ### By Treatment Type: Medications (Largest) vs. Therapeutic Procedures (Fastest-Growing) In the US opioid withdrawal-treatment market, the medications segment holds the largest market share, being favored due to their effectiveness in managing withdrawal symptoms. This segment encompasses various pharmacological options, including methadone, buprenorphine, and naltrexone, which are critical in helping individuals cope with opioid dependence. Conversely, therapeutic procedures, while currently smaller in market share, are rapidly gaining traction as alternative treatment approaches, offering innovative solutions that enhance patient care and recovery outcomes. The growth trends within this segment are driven by increasing awareness of opioid addiction, evolving treatment paradigms, and an emphasis on patient-centered care. The surging interest in holistic treatment options is propelling psychological counseling and support groups to emerge as essential components of recovery, aligning well with contemporary perspectives that value comprehensive and multi-faceted treatment approaches. This growth is further supported by state initiatives and federal funding aimed at combating the opioid crisis, leading to increased adoption of varied treatment modalities. Medications: Dominant vs. Psychological Counseling: Emerging Medications, as the dominant treatment type in the US opioid withdrawal-treatment market, provide essential support to patients during the challenging withdrawal phase. Their effectiveness in alleviating cravings and physical symptoms positions them as a cornerstone of treatment protocols. On the other hand, psychological counseling serves as an emerging treatment type that focuses on addressing the underlying psychological factors contributing to addiction. This integrative approach is gaining significance as awareness grows about the necessity of mental health support in recovery. By combining medication management with psychological counseling, treatment providers aim to enhance recovery rates, reduce the likelihood of relapse, and foster a supportive environment for individuals seeking to overcome opioid dependence. ### By Route of Administration: Oral (Largest) vs. Injectable (Fastest-Growing) In the US opioid withdrawal-treatment market, the route of administration segment showcases distinct preferences among healthcare professionals and patients alike. Oral administration is the most widely adopted method, capturing the largest share of the market due to its convenience and compliance advantages. Injectable and transdermal routes also play significant roles, yet they hold a smaller market share compared to the oral segment. On the other hand, nasal administration is gradually gaining traction, though still minor in the overall distribution. Growth trends in this segment reveal a shift towards non-invasive treatment methods, particularly the rising preference for oral solutions. This shift is driven by an increasing emphasis on patient comfort and adherence to treatment protocols. The injectable route is emerging as the fastest-growing segment due to its efficacy in acute withdrawal management, prompting innovation and new product development to cater to this demand. Furthermore, healthcare systems are actively shifting resources towards more effective and patient-friendly options, thus influencing the growth of these routes. Oral (Dominant) vs. Injectable (Emerging) Oral administration remains the dominant route in the US opioid withdrawal-treatment market, driven by its ease of use, patient acceptability, and consistent dosing. Patients are more likely to adhere to treatment regimens that involve oral medications, resulting in improved recovery outcomes. Despite this dominance, injectable administration is quickly emerging, particularly for patients requiring rapid intervention during acute withdrawal episodes. The injectable forms, such as naloxone, offer rapid action and are vital for emergency situations. However, their requirement for skilled healthcare professionals for administration can limit their broader application. This dynamic between oral and injectable methods highlights the market's ongoing evolution and the necessity for diverse treatment options tailored to patient needs. ### By Patient Type: Inpatient (Largest) vs. Outpatient (Fastest-Growing) In the US opioid withdrawal-treatment market, the distribution of patient types reveals a significant predominance of inpatient care, which captures the largest share. This segment is favored due to the comprehensive support and monitoring it offers, benefiting patients with severe withdrawal symptoms. On the other hand, outpatient care has carved out a substantial niche, preferred by many due to cost-effectiveness and flexibility. Emergency treatments also play a crucial role, particularly in acute situations, although they represent a smaller portion of the overall treatment landscape. Recent growth trends highlight outpatient care as the fastest-growing segment, driven by increasing healthcare accessibility and the rising number of treatment programs emphasizing convenience. There is a notable shift towards integrating telemedicine and outpatient services, allowing for more personalized care and engagement. Additionally, a growing public awareness of opioid addiction and recovery options is fostering greater participation in outpatient programs, further accelerating this trend. Inpatient: Dominant vs. Outpatient: Emerging The inpatient segment is characterized by its structured, intensive treatment approach, crucial for managing the complexities of opioid withdrawal. Its dominance stems from the ability to provide 24/7 medical support, ensuring immediate intervention in case of severe withdrawal symptoms. Conversely, outpatient treatment is emerging as a viable alternative, attracting those seeking more flexible options that fit into their daily lives. This segment is particularly appealing to patients who have support networks at home and prefer to avoid the stigma associated with inpatient care. As healthcare systems adapt to the evolving needs of patients, both segments are likely to coexist, offering complementary benefits. ### By Age Group: Adults (Largest) vs. Adolescents (Fastest-Growing) In the US opioid withdrawal-treatment market, the age group of adults dominates, commanding a significant share compared to other segments, including children, adolescents, and the elderly. The prevalence of opioid-related issues in adults has historically placed this demographic at the forefront of treatment initiatives, resulting in consistently high market demand. Conversely, the adolescent segment is emerging as the fastest-growing demographic within this market. Increased awareness of opioid addiction among teens and rising treatment initiatives tailored for this age group drive its rapid expansion. This trend is further supported by educational programs and social campaigns aimed at prevention and rehabilitation, fostering a supportive environment for adolescent recovery efforts. Adults (Dominant) vs. Adolescents (Emerging) The adult demographic in the US opioid withdrawal-treatment market is characterized by a broad range of service needs and a variety of treatment options, from detoxification and counseling to medication-assisted treatments. This group often benefits from a diverse approach to treatment that includes both inpatient and outpatient services, reflecting the complex nature of opioid addiction. Meanwhile, the adolescent segment is gaining prominence; rapid growth in this group prompts new treatment methodologies tailored to younger patients. These methodologies include peer support programs and adapted therapeutic practices that resonate with younger audiences. As treatment resources become more youth-centric, this segment is expected to continue its upward trajectory in the market. ## Competitive Benchmarking the opioid withdrawal-treatment market characterizes a complex competitive landscape, driven by increasing demand for effective treatment options and a growing awareness of opioid addiction's societal impact. Key players such as Indivior PLC (GB), Mylan N.V. (US), and Teva Pharmaceutical Industries Ltd. (IL) are actively shaping this environment through various strategic initiatives. Indivior PLC (GB) focuses on innovation in drug formulations, particularly with its buprenorphine-based products, which are designed to enhance patient adherence and reduce withdrawal symptoms. Meanwhile, Mylan N.V. (US) emphasizes regional expansion and partnerships to broaden its market reach, particularly in underserved areas. Teva Pharmaceutical Industries Ltd. (IL) is leveraging its extensive generics portfolio to provide cost-effective alternatives, thereby positioning itself as a leader in affordability within the market.The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure appears moderately fragmented, with several players competing for market share while also collaborating on initiatives aimed at improving treatment accessibility. This collective influence of key players fosters a dynamic environment where innovation and strategic partnerships are paramount. In October Indivior PLC (GB) announced a collaboration with a leading telehealth provider to integrate digital health solutions into its treatment offerings. This strategic move is likely to enhance patient engagement and facilitate remote monitoring, thereby improving treatment outcomes. Such integration of technology into traditional treatment paradigms reflects a broader trend towards digitalization in healthcare. In September Mylan N.V. (US) launched a new formulation of its buprenorphine product, which is designed to provide a more stable release profile. This innovation is expected to address patient needs more effectively and may lead to increased market penetration. The introduction of this product underscores Mylan's commitment to enhancing treatment efficacy and patient satisfaction. In August Teva Pharmaceutical Industries Ltd. (IL) expanded its distribution network by partnering with community health organizations across the US. This initiative aims to improve access to opioid withdrawal treatments in rural and underserved areas, thereby addressing a critical gap in the market. Such strategic alliances not only enhance Teva's market presence but also contribute to broader public health goals. As of November current competitive trends in the opioid withdrawal-treatment market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technology integration, and supply chain reliability, reflecting a more sophisticated approach to addressing the complexities of opioid addiction. ## Recent News & Developments The US Opioid Withdrawal Treatment Market has been witnessing significant developments recently, particularly as the demand for effective treatment options continues to grow amid the opioid crisis. As of October 2023, companies like Indivior and Alkermes are advancing therapeutic solutions, with Indivior focusing on innovative formulations for opioid addiction treatment. RiverMend Health has also expanded its services to provide comprehensive care for individuals dealing with substance use disorders. Notably, in March 2023, Purdue Pharma announced a settlement on its bankruptcy plan, aiming to direct funds toward addiction treatment initiatives, which reflects a shift in corporate responsibility amid ongoing litigation related to the opioid epidemic. Moreover, Zynerba Pharmaceuticals is making strides in cannabinoid-based therapies, enhancing the scope of treatment methods available. In terms of mergers and acquisitions, in April 2023, Appian Health announced a strategic acquisition to bolster its treatment infrastructure. The market valuation continues to rise as legislative changes support increased funding for addiction treatment services, driving growth for key players like Braeburn Pharmaceuticals and Thermo Fisher Scientific. Over the past two years, the focus on integrated treatment approaches has gained momentum, allowing companies to play a more pivotal role in combating opioid dependence in the US. ## Report Scope | MARKET SIZE 2024 | 675.69(USD Million) | | --- | --- | | MARKET SIZE 2025 | 710.49(USD Million) | | MARKET SIZE 2035 | 1173.96(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.15% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Indivior PLC (GB), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (IL), Alkermes PLC (IE), Purdue Pharma L.P. (US), Horizon Therapeutics PLC (IE), NantKwest Inc. (US), Camurus AB (SE) | | Segments Covered | Treatment Type, Route of Administration, Patient Type, Age Group | | Key Market Opportunities | Integration of digital therapeutics and telehealth solutions enhances access to opioid withdrawal-treatment. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the opioid withdrawal-treatment market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US opioid withdrawal-treatment market in 2024?** A: The market valuation was $675.69 Million in 2024. **Q: What is the projected market valuation for the US opioid withdrawal-treatment market by 2035?** A: The projected valuation for 2035 is $1,173.96 Million. **Q: What is the expected CAGR for the US opioid withdrawal-treatment market during the forecast period 2025 - 2035?** A: The expected CAGR is 5.15% during the forecast period 2025 - 2035. **Q: Which treatment types contributed to the market in 2024?** A: In 2024, medications contributed $300.0 - $500.0 Million, therapeutic procedures $150.0 - $250.0 Million, psychological counseling $125.0 - $200.0 Million, and support groups $100.0 - $223.96 Million. **Q: What are the leading routes of administration for opioid withdrawal treatments?** A: The leading routes of administration include oral ($135.0 - $225.0 Million), injectable ($180.0 - $300.0 Million), transdermal ($90.0 - $150.0 Million), and nasal ($270.69 - $478.96 Million). **Q: How did the patient type segmentation perform in 2024?** A: In 2024, outpatient treatments generated $300.0 - $500.0 Million, inpatient treatments $135.69 - $230.96 Million, and emergency treatments $240.0 - $443.0 Million. **Q: What age groups are targeted in the US opioid withdrawal-treatment market?** A: The market targets children ($50.0 - $80.0 Million), adolescents ($100.0 - $150.0 Million), adults ($400.0 - $650.0 Million), and the elderly ($125.69 - $193.96 Million). **Q: Who are the key players in the US opioid withdrawal-treatment market?** A: Key players include Indivior PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Alkermes PLC, Purdue Pharma L.P., Horizon Therapeutics PLC, NantKwest Inc., and Camurus AB. **Q: What trends are expected in the US opioid withdrawal-treatment market by 2035?** A: By 2035, the market is likely to expand significantly, driven by an increasing focus on effective treatment options and a projected valuation of $1,173.96 Million. **Q: How does the market's growth potential appear in the context of current treatment options?** A: The market's growth potential appears robust, with a projected CAGR of 5.15% indicating a sustained demand for innovative treatment solutions. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-opioid-withdrawal-treatment-market-17634*